Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyTransplantationDiseaseMalignant MeningitisNHL, B-Cell Type, Diffuse Large CellNHL, B-cell type, primary Lymphoma of the central nervous system SubgroupLymphomatous MeningitisICD10C79.3C83.3MeSHCentral Nervous System NeoplasmsMeningeal CarcinomatosisSequenceFreiburg CNS-NHL StudyMARTA: RITU375/MTRX3500/CYTA2000, NHL, CNS-NHL, Ind. (PID2965) -|- MARTA - RITU375/BSLF3,2/THTP5, Cons. (PID2966)MATRIXMTRX8000/RITU375/TMZL150, CNS lymphoma, C1 (PID1859) -|- C2 (PID1860) -|- C3 (PID1861) -|- C4 (PID1864) -|- C5 (PID1865) -|- C6 (PID1866)POMA5/DEXA40, NHL, CNS-NHL, C1-2 (PID3279) -|- POMA5, C3+ (PID3280)R-MP (RITU375/MTRX3000/PRCR60), CNS Lymphoma, C1 (PID1191) -|- C2-3 (PID1030) -|- PRCR100, maint. (PID1031)RITU375/MTRX3500/PRCR100/VNCR2, CNS lymphoma, C1-3 (PID1896) -|- RITU375/CYTA3000, C4-6 (PID1901)RITU375/TMZL150, NHL, C1-4 (PID3275) -|- RITU375/TMZL150 - TMZL150, C5-12 (PID3276)RITU750/TMZL150, CNS-NHL, ind. (PID2437) -|- TMZL150, cons. (PID2438) -|- MTPR1, maint. (PID2439)ChemotherapyChemo-substanceBusulfanCarboplatinCarmustineCytarabineDexamethasoneEtoposideIbrutinibIfosfamideMethotrexateMethylprednisolonePomalidomideProcarbazineRituximabTemozolomideThiotepaVincristineZanubrutinibChemo-substanceBusulfanCarboplatinCarmustineCytarabineDexamethasoneEtoposideIbrutinibIfosfamideMethotrexateMethylprednisolonePomalidomideProcarbazineRituximabTemozolomideThiotepaVincristineZanubrutinibChemo-substanceBusulfanCarboplatinCarmustineCytarabineDexamethasoneEtoposideIbrutinibIfosfamideMethotrexateMethylprednisolonePomalidomideProcarbazineRituximabTemozolomideThiotepaVincristineZanubrutinibChemo-substanceBusulfanCarboplatinCarmustineCytarabineDexamethasoneEtoposideIbrutinibIfosfamideMethotrexateMethylprednisolonePomalidomideProcarbazineRituximabTemozolomideThiotepaVincristineZanubrutinibNo. Substances12345 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamLevofloxacinMesnaNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateValaciclovirSupportive substanceAcetylsalicylic acidAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamLevofloxacinMesnaNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateValaciclovirSupportive substanceAcetylsalicylic acidAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamLevofloxacinMesnaNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateValaciclovirSupportive substanceAcetylsalicylic acidAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamLevofloxacinMesnaNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateValaciclovirNo. Substances1345789111213141516Protocol classificationTherapy classificationalternativecurrent standardIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseautologous stem cell transplantationConsolidationInductionMaintenanceTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHepatotoxicityHyperbilirubinemiaHyperglycemiaHyperkalemiaHypertriglyceridemiaHypocalcemiaHypokalemiaHyponatremiaIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaMucositisNephrotoxicityNeuropathyNeutropeniaPneumonitisPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorBatchelor TTBirnbaum TFerreri AJFritsch KGrommes CHouillier CIllerhaus GLin ZNayak LRubenstein JRubenstein JLSchorb ETun HWWong ETDiseaseErstdiagnose eines primären NHL des ZNS, 18-65 Jahreneudiagnostiziertes primäres ZNS-Lymphom, > 60 JahreNeudiagnostiziertes primäres ZNS-Lymphom, > 65 Jahre, ECOG 0-2Neu diagnostiziertes primäres ZNS-Lymphom, > 66 Jahre, Karnofsky > 70neudiagnostiziertes primäres ZNS-Lymphom, > 66 Jahre, Karnofsky > 70neudiagnostiziertes primäres ZNS-Lymphom, ECOG 0-2Neudiagnostiziertes primäres ZNS-Lymphom, ECOG 0-2Primäres ZNS-LymphomPrimäres ZNS-Lymphom, RezidivtherapiePrimäres ZNS-Lymphom, Rezidivtherapie, ECOG 0-3primäres ZNS-Lymphom, Rezidivtherapie, Karnofsky Status größer 60%primäres ZNS-NHL, ErstdiagnoseWiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50Zentrales B-NHL, Erstlinie, ECOG 0-3OriginAlbert-Ludwigs University, Freiburg, Germany, Freiburger ZNS-NHL ProtokollBrain Tumor Center and Neuro-Oncology Unit, Harvard Medical School/Beth Israel Deaconess Medical Center, Boston, USADepartment of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Primain StudyDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Neurology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, USA, North American Brain Tumor ConsortiumDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New YorkDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkHelen Diller Comprehensive Cancer Center, University of California, San Francisco, CALGB 50202 (Alliance 50202)IRCCS San Raffaele Scientific Institute, Milan, Italy, IELSG32 trialMATRix / IELSG43 StudieMayo Clinic, Jacksonville, FLStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, USAUniversites Paris, Paris, France, LOC network studyUniversity of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, MARTA trialProtokolle in Überarbeitung 34 protocols foundCytarabine 2000 / Etoposide 5, primary lymphoma of the central nervous system, cycle 6 (PID1866 V1.1)Cytarabine 3000 / Zanubrutinib 160, primary lymphoma of the central nervous system (PID3282 V1.0)Ibrutinib 840, primary lymphoma of the central nervous system (PID3281 V1.0)MARTA - Rituximab 375 / Busulfan 3.2 / Thiotepa 5, primary central nervous system Lymphoma, consolidation therapy (PID2966 V1.0)MARTA - Rituximab 375 / Methotrexate 3500 / Cytarabine 2000, primary central nervous system Lymphoma, induction (PID2965 V1.0)MATRIX - Carmustine 400 / Thiotepa 5, primary Lymphoma of the central nervous system, Stem Cell Transplantation, Autologous, MA (PID890 V2.2)MATRIX - Rituximab 375 / Carboplatin 300 / Ifosfamide 1.5 / Etoposide 100 / Dexamethasone 40, primary central nervous system Lymphoma, consolidation therapy (PID831 V2.1)MATRIX - Rituximab 375 / Methotrexate 3500 / Cytarabine 2000 / Thiotepa 30, primary central nervous system Lymphoma, induction (PID703 V2.2)Methotrexate 500/3000, Malignant Meningitis (PID1000 V1.0)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 1 (PID1859 V1.1)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 2 (PID1860 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 3 (PID1861 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, cycle 4 (PID1864 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, cycle 5 (PID1865 V1.3)Methylprednisolone 1000, primary Lymphoma of the central nervous system, maintenance (PID2439 V1.0)Pomalidomide 5 / Dexamethasone 40 - Pomalidomide 5, primary central nervous system Lymphoma, maintenance cycle (PID3280 V1.0)Pomalidomide 5 / Dexamethasone 40, primary central nervous system Lymphoma, cycles 1–2 (PID3279 V1.0)Rituximab 25, Malignant Meningitis (PID2571 V1.0)Rituximab 375 / Carmustine 400 / Thiotepa 5, primary central nervous system Lymphoma, conditioning, cycle 5 (PID1883 V1.0)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, primary central nervous system Lymphoma, induction, cycle 3 (PID1881 V1.0)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, primary central nervous system Lymphoma, induction, cycle 4 (PID1882 V1.0)Rituximab 375 / Cytarabine 3000, primary central nervous system Lymphoma, cycles 4?6 (PID1901 V1.1)Rituximab 375 / Methotrexate 3000 / Procarbazine 60 - Procarbazine 100, maintenance, primary central nervous system Lymphoma (PID1031 V1.3)Rituximab 375 / Methotrexate 3000 / Procarbazine 60, primary central nervous system Lymphoma, Cycle 1 (PID1191 V1.4)Rituximab 375 / Methotrexate 3000 / Procarbazine 60, primary central nervous system Lymphoma, cycles 2?3 (PID1030 V2.4)Rituximab 375 / Methotrexate 3500 / Procarbazine 100 / Vincristine 2, primary central nervous system Lymphoma, cycles 1-3 (PID1896 V1.3)Rituximab 375 / Methotrexate 4000 / Ifosfamide 1.5, primary lymphoma of the central nervous system (PID3216 V1.0)Rituximab 375 / Methotrexate 8000, primary central nervous system Lymphoma, induction, cycle 1 (PID1879 V1.2)Rituximab 375 / Methotrexate 8000, primary central nervous system Lymphoma, induction, cycle 2 (PID1880 V1.2)Rituximab 375 / Temozolomide 150 - Temozolomide 150, primary central nervous system Lymphoma, cycles 5–12 (PID3276 V1.0)Rituximab 375 / Temozolomide 150, primary central nervous system Lymphoma, cycles 1–4 (PID3275 V1.0)Rituximab 375, primary lymphoma of the central nervous system (PID3277 V1.0)Rituximab 750 / Temozolomide 150, primary central nervous system Lymphoma, induction therapy (PID2437 V1.0)Temozolomide 150, primary central nervous system Lymphoma, consolidation therapy (PID2438 V1.0)
